We just covered the 10 Best Non-AI Stocks to Buy According to Billionaire Stanley Druckenmiller.
Natera, Inc. (NASDAQ:NTRA) ranks #1 (see 5 Best Non-AI Stocks to Buy According to Billionaire Stanley Druckenmiller)
Natera (NASDAQ:NTRA) develops genetic testing products used mainly in cancer detection, pregnancy screening, and organ health monitoring. Its key product is Signatera, a cancer testing platform that helps doctors monitor cancer recurrence. Natera (NASDAQ:NTRA) says about 50% of oncologists are already ordering Signatera.
In Q1, revenue rose about 38% year over year while test volumes jumped 18.5% year over year. Some notable news for the stock includes FDA approvals like Signatera for bladder cancer, expanding Medicare reimbursement coverage, increasing adoption in international markets like Japan and expansion via acquisitions ( Foresight Diagnostics). Baron Health Care Fund stated the following regarding Natera, Inc. (NASDAQ:NTRA) in its Q1 2026 investor letter: “We reacquired shares of Natera, Inc. (NASDAQ:NTRA), a diagnostics company that provides testing services in the oncology, prenatal, and organ transplant settings.